CAJ | 학술논문

目的探讨黏着斑蛋白(Kindlin-2)在肝细胞癌(简称肝癌)中表达的临床意义及其与肝癌血管生成的关系。方法采用逆转录-聚合酶链反应( RT-PCR)方法检测12例原发性肝癌及癌旁配对组织和6例正常肝组织中Kindlin-2基因的表达水平。采用免疫组化方法检测69例原发性肝癌患者癌组织及癌旁组织中Kindlin-2蛋白的表达情况,以及肝癌组织中血管内皮生长因子( VEGF)和CD34的表达量。结果Kindlin-2在肝癌组织中的表达明显高于癌旁及正常肝组织；Kindlin-2的表达与肿瘤直径(P=0.010)、门静脉侵犯(P=0.025)相关；肝癌组织中 Kindlin-2表达与 VEGF表达呈正相关(r=0.401, P=0.001),且Kindlin-2阳性者微血管密度(MVD)值高于阴性者,差异有统计学意义(P<0.01)。结论肝癌组织中异常表达增高的Kindlin-2与肿瘤微血管生呈正相关,提示Kindlin-2可能成为肝癌抗血管治疗的潜在靶点。
목적탐토점착반단백(Kindlin-2)재간세포암(간칭간암)중표체적림상의의급기여간암혈관생성적관계。방법채용역전록-취합매련반응( RT-PCR)방법검측12례원발성간암급암방배대조직화6례정상간조직중Kindlin-2기인적표체수평。채용면역조화방법검측69례원발성간암환자암조직급암방조직중Kindlin-2단백적표체정황,이급간암조직중혈관내피생장인자( VEGF)화CD34적표체량。결과Kindlin-2재간암조직중적표체명현고우암방급정상간조직；Kindlin-2적표체여종류직경(P=0.010)、문정맥침범(P=0.025)상관；간암조직중 Kindlin-2표체여 VEGF표체정정상관(r=0.401, P=0.001),차Kindlin-2양성자미혈관밀도(MVD)치고우음성자,차이유통계학의의(P<0.01)。결론간암조직중이상표체증고적Kindlin-2여종류미혈관생정정상관,제시Kindlin-2가능성위간암항혈관치료적잠재파점。
Objective To explore the clinical significance of Kindlin-2 expression in hepatocellular carcinoma ( HCC) and its relationship with HCC angiogenesis. Methods RT-PCR was performed to detect the gene expres-sion of Kindlin-2 in 12 cases of primary HCC tissues and adjacent tissues, and 6 cases of normal liver tissues. Im-munohistochemistry was used to determine the protein expression of Kindlin-2 in HCC and adjacent tissues from 69 primary HCC patients. Furthermore, vascular endothelial growth factor ( VEGF) and CD34 were also examined in HCC tissues mentioned above. Results Kindlin-2 expression appeared at a high level compared to adjacent tissues and normal liver tissues. The expression of Kindlin-2 was associated with tumor diameter ( P=0.010 ) and portal venous invasion ( P=0.025 ) . The expression of Kindlin-2 in HCC was positively correlated with VEGF expression (r=0.401, P=0.001);besides, tumors with Kindlin-2 positive expression exhibited higher MVD than that nega-tive expression tumors(P<0.01). Conclusion Aberrant overexpression of Kindlin-2 in HCC is closely associated with tumor angiogenesis, and Kindlin-2 can be the potential targets of anti-angiogenesis therapy of HCC.